Leniolisib: a drug providing a promising avenue for the treatment of activated phosphoinositide 3-kinase δ syndrome (APDS).
作者信息
Ali Anoshia, Qureshi Amsal, Shigri Anum Fatima, Alvi Areesha Moiz, Malikzai Abdullah
机构信息
Agha Khan University hospital (AKU).
Agha Khan University hospital (AKU) Karachi, Pakistan.
出版信息
Ann Med Surg (Lond). 2024 May 20;86(7):3812-3813. doi: 10.1097/MS9.0000000000002189. eCollection 2024 Jul.
Abstract
摘要
相似文献
1
Leniolisib: a drug providing a promising avenue for the treatment of activated phosphoinositide 3-kinase δ syndrome (APDS).来尼利西布：一种为治疗活化磷脂酰肌醇3激酶δ综合征（APDS）提供了一条有前景途径的药物。
Ann Med Surg (Lond). 2024 May 20;86(7):3812-3813. doi: 10.1097/MS9.0000000000002189. eCollection 2024 Jul.
2
Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.使用PI3Kδ抑制剂来那度胺进行有效的“活化PI3Kδ综合征”靶向治疗。
Blood. 2017 Nov 23;130(21):2307-2316. doi: 10.1182/blood-2017-08-801191. Epub 2017 Sep 29.
3
PI3Kδ Pathway Dysregulation and Unique Features of Its Inhibition by Leniolisib in Activated PI3Kδ Syndrome and Beyond.PI3Kδ 通路失调及 Leniolisib 对其的抑制作用在活化的 PI3Kδ 综合征及其他疾病中的独特特征。
J Allergy Clin Immunol Pract. 2024 Jan;12(1):69-78. doi: 10.1016/j.jaip.2023.09.016. Epub 2023 Sep 28.
4
Leniolisib: First Approval.利尼利昔布：首次获批
Drugs. 2023 Jul;83(10):943-948. doi: 10.1007/s40265-023-01895-4.
5
APDS patients with immune-complex vasculitis and resolution with leniolisib.患有免疫复合物性血管炎且使用来尼利西布后病情缓解的活化磷脂酰肌醇3激酶δ综合征（APDS）患者。
Clin Immunol. 2024 May;262:110176. doi: 10.1016/j.clim.2024.110176. Epub 2024 Mar 8.
6
Interim analysis: Open-label extension study of leniolisib for patients with APDS.临时分析：APDS 患者用 leniolisib 的开放标签扩展研究。
J Allergy Clin Immunol. 2024 Jan;153(1):265-274.e9. doi: 10.1016/j.jaci.2023.09.032. Epub 2023 Oct 4.
7
A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome.一项针对激活的 PI3Kδ 综合征的 PI3Kδ 抑制剂 leniolisib 的随机、安慰剂对照 3 期试验。
Blood. 2023 Mar 2;141(9):971-983. doi: 10.1182/blood.2022018546.
9
ANCA vasculitis expands the spectrum of autoimmune manifestations of activated PI3 kinase δ syndrome.抗中性粒细胞胞浆抗体血管炎扩大了活化磷脂酰肌醇-3激酶δ综合征自身免疫表现的范围。
Front Pediatr. 2023 May 19;11:1179788. doi: 10.3389/fped.2023.1179788. eCollection 2023.
10
Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kδ Syndrome (APDS): a Systematic Review.PI3Kδ 综合征（APDS）患者的临床、免疫学和遗传学特征：系统评价。
Clin Rev Allergy Immunol. 2020 Dec;59(3):323-333. doi: 10.1007/s12016-019-08738-9.
本文引用的文献
1
A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome.一项针对激活的 PI3Kδ 综合征的 PI3Kδ 抑制剂 leniolisib 的随机、安慰剂对照 3 期试验。
Blood. 2023 Mar 2;141(9):971-983. doi: 10.1182/blood.2022018546.
2
Disorders Related to PI3Kδ Hyperactivation: Characterizing the Clinical and Immunological Features of Activated PI3-Kinase Delta Syndromes.与PI3Kδ过度激活相关的疾病：活化磷脂酰肌醇-3激酶δ综合征的临床和免疫学特征
Front Pediatr. 2021 Aug 5;9:702872. doi: 10.3389/fped.2021.702872. eCollection 2021.
3
Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence.儿童和青少年期活化磷脂酰肌醇3-激酶δ综合征的自然病程
Front Pediatr. 2021 Jul 19;9:697706. doi: 10.3389/fped.2021.697706. eCollection 2021.
4
Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.使用PI3Kδ抑制剂来那度胺进行有效的“活化PI3Kδ综合征”靶向治疗。
Blood. 2017 Nov 23;130(21):2307-2316. doi: 10.1182/blood-2017-08-801191. Epub 2017 Sep 29.
5
PI3Kδ and primary immunodeficiencies.磷脂酰肌醇-3激酶δ与原发性免疫缺陷
Nat Rev Immunol. 2016 Nov;16(11):702-714. doi: 10.1038/nri.2016.93. Epub 2016 Sep 12.
Zotero 插件